Developing a Highly Potent & Selective CCR4 Small Molecule Antagonist FLX475 to Target Treg Selectively in the TME

Time: 12:30 pm
day: Day Two | Track B | Afternoon


  • Discussing current challenges to effectively target regulatory T cells in the TME
  • Deploying a computational biology and large dataset approach to drug development and patient selection strategies
  • Review of clinical status of FLX475